| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/06/2009 | US20090196932 Pharmaceutical compositions of atorvastatin |
| 08/06/2009 | US20090196924 Controlled-release lamotrigine formulations |
| 08/06/2009 | US20090196923 Controlled release formulation comprising anti-epileptic drugs |
| 08/06/2009 | US20090196919 Oxcarbazepine dosage forms |
| 08/06/2009 | US20090196876 Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| 08/06/2009 | US20090196867 Soy kefir powder and uses thereof |
| 08/06/2009 | US20090196862 High dosage Vitamin D |
| 08/06/2009 | US20090196859 Oligodendrocyte Precursor Cell Composition and Methods of Use |
| 08/06/2009 | US20090196858 Ameliorating agent for brain damage |
| 08/06/2009 | US20090196854 Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
| 08/06/2009 | US20090196834 Tobacco alkaloid releasing chewing gum |
| 08/06/2009 | DE102008007218A1 Preventive treatment of patients with mild cognitive disorders, which based on increase of circulation-relevant peptide-biomarker measurable in circulation, with medicament comprising e.g. angiotensin converting enzyme-inhibitor |
| 08/06/2009 | CA2751058A1 Corroles for neuroprotection and neurorescue |
| 08/06/2009 | CA2728808A1 Pulmonary formulations of triptans |
| 08/06/2009 | CA2714008A1 2-amino quinoline derivatives useful as inhibitors of .beta.-secretase (bace) |
| 08/06/2009 | CA2713998A1 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace) |
| 08/06/2009 | CA2713808A1 Novel salts of o-desmethyl-venlafaxine |
| 08/06/2009 | CA2713784A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
| 08/06/2009 | CA2713598A1 Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| 08/06/2009 | CA2713256A1 Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta |
| 08/06/2009 | CA2713253A1 Substituted arylamide oxazepinopyrimidone derivatives |
| 08/06/2009 | CA2713248A1 Substituted heteroarylamide oxazepinopyrimidone derivatives |
| 08/06/2009 | CA2713163A1 Galenic form for the oral transmucosal delivery of triptans |
| 08/06/2009 | CA2712897A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| 08/06/2009 | CA2712888A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| 08/06/2009 | CA2712885A1 Substituted pyridazine derivatives which have histamine h3 antagonist activity |
| 08/06/2009 | CA2712095A1 Crystalline cinnamide compounds or salts thereof |
| 08/06/2009 | CA2711774A1 Fentanyl-containing patch for external use |
| 08/06/2009 | CA2711575A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/05/2009 | EP2085484A1 Method for identification of compound having antianxiety effect |
| 08/05/2009 | EP2085402A1 Phosphates of secondary alcohols |
| 08/05/2009 | EP2085400A1 Substituted heteroarylamide oxazepinopyrimidone derivatives |
| 08/05/2009 | EP2085399A1 substituted arylamide oxazepinopyrimidone derivatives |
| 08/05/2009 | EP2085398A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/05/2009 | EP2085389A1 Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
| 08/05/2009 | EP2085388A1 Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
| 08/05/2009 | EP2085387A1 Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents |
| 08/05/2009 | EP2085377A1 Novel salts of O-desmethyl-venlafaxine |
| 08/05/2009 | EP2085120A1 The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| 08/05/2009 | EP2085094A2 Application of aminopeptidases inhibitors and pharmaceutical preparations containing same |
| 08/05/2009 | EP2085093A1 Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen |
| 08/05/2009 | EP2085089A1 Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior |
| 08/05/2009 | EP2085087A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 08/05/2009 | EP2085086A2 Method for treating congestive heart failure or diabetic nephropathy |
| 08/05/2009 | EP2085082A1 Treatment of cognitive decline |
| 08/05/2009 | EP2085081A1 3-(2-dimethyl amino methyl-cyclohexyl) phenol for treating polyneuropathic pain |
| 08/05/2009 | EP2085078A1 Controlled porosity osmotic pump tablet of high permeable drugs and the preparation method thereof |
| 08/05/2009 | EP2084163A2 Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 08/05/2009 | EP2084145A2 (s)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use |
| 08/05/2009 | EP2084141A1 Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| 08/05/2009 | EP2084140A1 Arginine derivatives with np-i antagonistic activity |
| 08/05/2009 | EP2084133A2 Process for preparing crystalline aripiprazole |
| 08/05/2009 | EP2084131A1 Indole and benzofuran 2-carboxamide derivatives |
| 08/05/2009 | EP2083921A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| 08/05/2009 | EP2083837A1 Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent |
| 08/05/2009 | EP2083821A1 Novel 4-amino-pyridine derivatives and their use as potassium channel modulators |
| 08/05/2009 | EP2083819A2 Pde10 inhibitors and related compositions and methods |
| 08/05/2009 | EP2083814A1 Dmae as sole agent for the treatment of mild cognitive impairment |
| 08/05/2009 | EP2083811A1 Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
| 08/05/2009 | EP2083808A1 Use of buprenorphine or n-alkylated derivatives thereof for wound healing |
| 08/05/2009 | EP2029559B1 Aryl-4-ethynyl-isoxazole derivatives |
| 08/05/2009 | EP1924560B1 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 08/05/2009 | EP1771178B1 Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies |
| 08/05/2009 | EP1745010B1 Substituted cyclohexyl-1,4-diamine derivatives |
| 08/05/2009 | EP1742707A4 Treatment of cns disorders using cns target modulators |
| 08/05/2009 | EP1699454B1 Pyrazole derivatives and use thereof as orexin receptor antagonists |
| 08/05/2009 | EP1641457B1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 08/05/2009 | EP1635799B1 Pharmaceutical formulations of amyloid inhibiting compounds |
| 08/05/2009 | EP1560837B1 Novel ampiphilic derivatives of alpha-c-phenyl n-tert-butyl nitrone |
| 08/05/2009 | EP1509506B1 Pyridazine derivatives |
| 08/05/2009 | EP1503778B1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 08/05/2009 | EP1499735B1 Optimization of transgene expression in mammalian cells |
| 08/05/2009 | EP1473289B1 Preventives or remedies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds |
| 08/05/2009 | EP1465880B1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use to treat disorders associated with somatostatine |
| 08/05/2009 | EP1442115B1 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
| 08/05/2009 | EP1407004B1 Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease |
| 08/05/2009 | EP1399445B1 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| 08/05/2009 | EP1357111B1 2-pyridone derivatives having affinity for cannabinoid type 2 receptor |
| 08/05/2009 | EP1341786B9 Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain |
| 08/05/2009 | EP1186594B1 N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same |
| 08/05/2009 | CN101501041A Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia |
| 08/05/2009 | CN101501040A Amino-imidazolones and their use as a medicament for treating cognitive impairment, Alzheimer disease, neurodegeneration and dementia |
| 08/05/2009 | CN101501038A Fused [d]pyridazin-7-ones |
| 08/05/2009 | CN101501032A Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| 08/05/2009 | CN101501025A Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
| 08/05/2009 | CN101501024A Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
| 08/05/2009 | CN101501022A Benzimidazole derivatives which are to be used as anatgonis for the CB1-receptor |
| 08/05/2009 | CN101501021A Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
| 08/05/2009 | CN101501008A Arylpiperazine derivatives and uses thereof |
| 08/05/2009 | CN101500998A Mono-and divalent salts of N-(5-hydroxynicotinoil)-L-glutaminic acid exhibiting psychotropic (antidepressant and anxyolytic), neuroprotective, heroprotective and cerebroprotective action |
| 08/05/2009 | CN101500611A Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity |
| 08/05/2009 | CN101500588A Novel agents for the treatment of disorders connected to impaired neurotransmission |
| 08/05/2009 | CN101500575A Thienopyrimidines useful as modulators of ion channels |
| 08/05/2009 | CN101500570A Novel tape preparation |
| 08/05/2009 | CN101500567A Use of a P38 kinase inhibitor for treating psychiatric disorders |
| 08/05/2009 | CN101500565A Modulators of muscarinic receptors |
| 08/05/2009 | CN101500563A Cycloalkanopyrolocarbazole derivatives and the use thereof as PARP, VEGFR2 and MLK3 inhibitors |
| 08/05/2009 | CN101500559A Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| 08/05/2009 | CN101497655A Polypeptide hydration salt compound and use for anti-depression aspect |
| 08/05/2009 | CN101497619A Method for the manufacture of THIP |